| P50 | author | Oliver Pfaar | Q87632159 |
| | Roy Gerth van Wijk | Q88142611 |
| P2860 | cites work | Injection allergen immunotherapy for asthma | Q24236566 |
| | Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials | Q24563083 |
| | EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy | Q30394524 |
| | Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens | Q33718981 |
| | Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma | Q34375745 |
| | Allergic rhinitis and its impact on asthma | Q34438438 |
| | The burden associated with ocular symptoms in allergic rhinitis | Q34637329 |
| | Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper | Q34754637 |
| | The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis | Q35005943 |
| | Rhinasthma: a new specific QoL questionnaire for patients with rhinitis and asthma. | Q35112407 |
| | The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA(2)LEN). | Q36216879 |
| | Control of Allergic Rhinitis and Asthma Test (CARAT) can be used to assess individual patients over time | Q36462907 |
| | Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. | Q36734980 |
| | Qualitative Development of the Rhinitis Control Assessment Test (RCAT), an Instrument for Evaluating Rhinitis Symptom Control | Q37978399 |
| | An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. | Q38153965 |
| | Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper | Q38206795 |
| | Update on house dust mite immunotherapy: are more studies needed? | Q38239234 |
| | Environmental exposure chambers in allergen immunotherapy trials: Current status and clinical validation needs | Q38295469 |
| | Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study | Q39017587 |
| | House dust mite allergy. | Q39819438 |
| | Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis | Q42756927 |
| | Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial | Q42972511 |
| | Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study | Q43646876 |
| | Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial | Q44545292 |
| | Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis | Q44621485 |
| | House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis | Q45057152 |
| | Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. | Q46714664 |
| | Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial | Q46981948 |
| | Impact of allergic rhinitis symptoms on quality of life in primary care | Q48209846 |
| | House dust mite sublingual immunotherapy: results of a US trial | Q48316239 |
| | Severity and impairment of allergic rhinitis in patients consulting in primary care | Q48518767 |
| | Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis | Q48911545 |
| | Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. | Q52090255 |
| | Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. | Q54420300 |
| | Study of prolonged hyposensitization with D. pteronyssinus extract in allergic rhinitis | Q59689649 |
| | Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites | Q60809793 |
| | House Dust Mite Sublingual Immunotherapy | Q62517550 |
| | A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results | Q68876155 |
| | Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis. A controlled clinical trial | Q70393295 |
| | Comparison of powder and aerosolized budesonide in perennial rhinitis: validation of rhinitis quality of life questionnaire | Q70607149 |
| | Seasonal variation in airway hyperresponsiveness and natural exposure to house dust mite allergens in patients with asthma | Q72273436 |
| | Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study | Q72996277 |
| | Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity | Q73317967 |
| | Immunomodulation during sublingual therapy in allergic children | Q73481524 |
| | A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults | Q73668948 |
| | Evaluation of impermeable covers for bedding in patients with allergic rhinitis | Q73683115 |
| | House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study | Q73714861 |
| | Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis | Q74309230 |
| | Prevalence and severity of allergic rhinitis in house dust mite-allergic patients with bronchial asthma or atopic dermatitis | Q74640917 |
| | Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study | Q77827539 |
| | Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis | Q79429562 |
| | Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy | Q79917788 |
| | Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma | Q80994348 |
| | Sublingual immunotherapy not effective in house dust mite-allergic children in primary care | Q82135331 |
| | Clinical effects of specific immunotherapy: a two-year double-blind, placebo-controlled study with a one year follow-up | Q82207423 |
| | Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan | Q82223243 |
| | Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study | Q82278399 |
| | Changes in serum specific IgG4 and IgG4/ IgE ratio in mite-sensitized Taiwanese children with allergic rhinitis receiving short-term sublingual-swallow immunotherapy: a multicenter, randomized, placebo-controlled trial | Q82830112 |
| | House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma | Q87434432 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 1-9 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Current treatment options in allergy | Q27725416 |
| P1476 | title | Mite-Allergic Rhinitis: How to Evaluate Clinical Efficacy in Allergen-Specific Immunotherapy Trials? | |
| P478 | volume | 2 | |